EMA's CMV immunoglobulin PSUSA ends in maintenance: what a quiet outcome tells PV teams
EMA has closed its periodic safety review of cytomegalovirus immunoglobulin with the marketing authorisations maintained. What the outcome does and does not tell MAHs is worth spelling out.
What happened
On 19 November 2026 the EMA published the outcome of a periodic safety update report single assessment (PSUSA) for cytomegalovirus immunoglobulin. The regulatory outcome is recorded as maintenance, so the marketing authorisations covered by the procedure are to stay in place.
The published record is brief. It does not say which safety data were reviewed, whether any signal was discussed, or whether the product information will change. The EMA's procedure page is the place to check for the full wording and any annexes. Until then, the only firm conclusion is that this review did not end in a variation, suspension or revocation of the authorisations.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- EMA publishes PSUSA outcome for cytomegalovirus immunoglobulin: marketing authorisations to be maintained EMA · Thu 19 Nov 2026
- EMA publishes PSUSA outcome for famciclovir with 'maintenance' regulatory result EMA · Thu 19 Nov 2026
- FDA creates CBER Safety Council to oversee postmarket safety of biologics FDA CBER · Thu 19 Nov 2026
- React Health recalls 7,533 Luna G3 BPAP devices over incorrect pressure data FDA MedWatch · Thu 19 Nov 2026
- FDA early alert: B. Braun updates Caresite Micro valve instructions over sticking piston FDA MedWatch · Thu 19 Nov 2026
- SÚKL publishes Czech national hemovigilance annual report for 2025 SÚKL · Thu 19 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Safety judgment belongs apart from the product line, and CBER just said so
FDA's new CBER Safety Council sits outside the product offices. PV leaders should test whether their own safety decisions have the same structural distance from commercial pressure.
Definitions decide pathways: UK gene therapy rewrite means check your category now
The UK will widen its gene therapy definition to catch synthetic and genome-editing products. Regulatory teams should test their pipelines against the new boundary before the legislation arrives.
Clearmind's Hong Kong PTSD patent application is published, not granted
A published application for psychedelic-derived PTSD compounds signals IP positioning, not clinical or regulatory progress. Trial teams should read it that way.